Is WuXi Biologics profitable in 2026?

Yes. FY2025 audited revenue reached RMB 21.8 billion, up 16.7% YoY, with gross margin expanding 500 basis points to 46.0% and adjusted gross profit up 25.5% YoY, per results reported March 24, 2026.

Could AI replace WuXi Biologics?

Unlikely soon. AI tools like AlphaFold speed up early discovery, but WuXi's core moat is physical GMP manufacturing capacity, 22+ FDA/EMA facility approvals, and 945 embedded multi-year client contracts as of Dec 31, 2025, none of which AI replaces.

Who is WuXi Biologics' biggest competitor?

Samsung Biologics, which as of October 2025 was explicitly marketing itself as a 'safe alternative' to WuXi and expanding US capacity toward 1.3 million liters by 2032, and Lonza, which acquired Genentech's Vacaville plant for $1.2 billion.

Who owns WuXi Biologics?

WuXi Biologics (Cayman) Inc. is a publicly listed company on the Hong Kong Stock Exchange (2269.HK) since June 2017, with no single controlling parent; founder Dr. Ge Li serves as non-executive Chairman, per company profile data as of February 27, 2026.

Will WuXi Biologics be added to the US BIOSECURE blacklist?

Unresolved as of mid-2026. A December 2025 congressional letter urged DoD to add WuXi Biologics and WuXi XDC to the 1260H list, but as of June 8, 2026 only WuXi AppTec appears there; OMB's formal covered-company list is due around December 18, 2026.

Is WuXi Biologics still growing despite US political pressure?

Yes, as of its March 24, 2026 annual results: revenue grew 16.7% YoY to RMB 21.8 billion in FY2025, continuing-operations revenue grew over 20%, and the company supported 945 integrated client projects including 25 in commercial manufacturing.

Biotech tools companies · China

WuXi Biologics

wuxibiologics.com ↗

Chinese CDMO that manufactures biologic drugs for global pharma clients under contract.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from around Dec 2026 · Every call on the record Checkpoint: OMB publishes its 'Biotechnology Companies of Concern' list under the BIOSECURE Act

The call

WuXi Biologics runs a large, profitable, well-approved manufacturing business whose main risk is a US government list, not a product or an algorithm.

WuXi Biologics makes medicines for pharmaceutical companies at facilities approved by US and European regulators, with nearly 1,000 long-term customer contracts. The company built trust over ten years, but a new US law passed in December 2025 targets Chinese biotech companies for national security reasons, and Samsung and Lonza are already telling customers they are safer choices. Everything depends on whether the US government officially bans WuXi Biologics by late 2026, which would force its customers to switch to competitors.

Why

AI pressure: None apparent. AI speeds up drug discovery elsewhere, but WuXi's manufacturing and GMP work sits downstream of that and isn't replaced by it. Could AI do the core job? Unlikely.

Bigger players: Samsung Biologics and Lonza. Both are live in the market, expanding US capacity and pitching themselves to pharma clients as the non-China alternative. Could a giant copy it? No, they are blocked.

What protects it. 22 combined FDA/EMA facility approvals and 945 embedded multi-year client programs that are costly and slow to move elsewhere.

What would change this call

OMB publishes 'Biotechnology Companies of Concern' list around Dec 18, 2026. Naming WuXi Biologics would trigger US client exits; exclusion would remove the overhang.
H1 2026 earnings (est. Aug 20, 2026) show US revenue or client count trend. Decline would confirm active US client attrition tied to BIOSECURE fears.
Samsung Biologics or Lonza announce new US contracts explicitly won from WuXi clients. Would confirm rivals are converting BIOSECURE anxiety into actual customer switches.

Key numbers

FY2025 revenue RMB 21.8bn, up 16.7% YoY (2026-03-24)
Gross margin 46.0%, up 500bps YoY (2026-03-24)
945 integrated client projects, 25 in commercial manufacturing (2025-12-31)

Named risks

OMB may explicitly name WuXi Biologics on BIOSECURE covered-company list by Dec 2026. Severity: high
US clients may shift to Samsung Biologics or Lonza as 'safe alternatives'. Severity: high
Congressional pressure to add WuXi Biologics and XDC to DoD 1260H list. Severity: medium
72% of headcount concentrated in China amid rising US geopolitical restrictions. Severity: medium
Integration execution risk from WuXi XDC's BioDlink acquisition completed March 2026. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Samsung Biologics	gaining on	Marketing as 'safe alternative' to WuXi, expanding US capacity toward 1.3M L by 2032, Oct 2025
Lonza	gaining on	Completed $1.2bn Genentech Vacaville plant acquisition, 2024
Fujifilm Diosynth Biotechnologies	contesting	Also facing US regulatory scrutiny alongside WuXi per Oct 2025 industry reporting

Questions people ask

Is WuXi Biologics profitable in 2026?: Yes. FY2025 audited revenue reached RMB 21.8 billion, up 16.7% YoY, with gross margin expanding 500 basis points to 46.0% and adjusted gross profit up 25.5% YoY, per results reported March 24, 2026.
Could AI replace WuXi Biologics?: Unlikely soon. AI tools like AlphaFold speed up early discovery, but WuXi's core moat is physical GMP manufacturing capacity, 22+ FDA/EMA facility approvals, and 945 embedded multi-year client contracts as of Dec 31, 2025, none of which AI replaces.
Who is WuXi Biologics' biggest competitor?: Samsung Biologics, which as of October 2025 was explicitly marketing itself as a 'safe alternative' to WuXi and expanding US capacity toward 1.3 million liters by 2032, and Lonza, which acquired Genentech's Vacaville plant for $1.2 billion.
Who owns WuXi Biologics?: WuXi Biologics (Cayman) Inc. is a publicly listed company on the Hong Kong Stock Exchange (2269.HK) since June 2017, with no single controlling parent; founder Dr. Ge Li serves as non-executive Chairman, per company profile data as of February 27, 2026.
Will WuXi Biologics be added to the US BIOSECURE blacklist?: Unresolved as of mid-2026. A December 2025 congressional letter urged DoD to add WuXi Biologics and WuXi XDC to the 1260H list, but as of June 8, 2026 only WuXi AppTec appears there; OMB's formal covered-company list is due around December 18, 2026.
Is WuXi Biologics still growing despite US political pressure?: Yes, as of its March 24, 2026 annual results: revenue grew 16.7% YoY to RMB 21.8 billion in FY2025, continuing-operations revenue grew over 20%, and the company supported 945 integrated client projects including 25 in commercial manufacturing.

Timeline

2026-06-08DoW 1260H list update names WuXi AppTec but not WuXi Biologics explicitly
2026-03-24FY2025 annual results reported record revenue RMB 21.8bn, up 16.7% YoY
2026-03-17WuXi XDC tender offer for BioDlink became unconditional
2025-12-18BIOSECURE Act signed into law as Section 851 of FY2026 NDAA
2025-12Congressional letter urged DoD to add WuXi Biologics and XDC to 1260H list
2025-10-29Samsung Biologics reported marketing itself as 'safe alternative' to WuXi
2025-08Dundalk, Ireland facility received first EMA approval for commercial biologic manufacturing
2023-11WuXi XDC bioconjugate unit spun off and separately listed on HKEX
2017-06WuXi Biologics IPO on HKEX raised roughly HK$3.98bn
2014-02-27WuXi Biologics founded as spinoff of WuXi AppTec's biologics division

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation